AZN
AstraZeneca PLC
NASDAQ: AZN · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$187.37
+1.17% today
Updated 2026-04-30
Market cap
$287.11B
P/E ratio
27.85
P/S ratio
4.89x
EPS (TTM)
$6.65
Dividend yield
—
52W range
$130 – $211
Volume
2.0M
AstraZeneca PLC (AZN) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-2.0%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+23.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+8.7%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+13.8%
2025-09-30
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-31 | $1.29 | +1.4% | $193.88 | $200.73 | +3.5% |
| 2025-09-30 | $1.19 | +4.9% | $74.13 | $84.36 | +13.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $1.27 | $1.29 | +1.4% | — | — |
| 2025-09-30 | $1.13 | $1.19 | +4.9% | $15.19B | +12.0% |
| 2025-06-30 | $1.46 | $1.09 | -25.9% | $14.46B | +11.7% |
| 2025-03-31 | $1.12 | $1.25 | +11.6% | $13.59B | +7.2% |
| 2024-12-31 | $1.04 | $1.05 | +0.8% | $14.89B | +23.8% |
| 2024-09-30 | — | $0.91 | — | $13.56B | +18.0% |
| 2024-06-30 | — | $1.24 | — | $12.94B | +13.3% |
| 2024-03-31 | — | $1.40 | — | $12.68B | — |
| 2023-12-31 | — | $0.62 | — | $12.02B | — |
| 2023-09-30 | — | $0.88 | — | $11.49B | — |
| 2023-06-30 | — | $1.17 | — | $11.42B | — |
| 2023-03-31 | — | $1.16 | — | — | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $5.25 | $64.8B | +10.3% | 1 | high |
| 2027 (E) | $5.91 | $69.0B | +6.4% | 1 | high |
| 2028 (E) | $6.50 | $74.2B | +7.5% | 1 | medium |
| 2029 (E) | $7.15 | $80.1B | +8.0% | 1 | medium |
| 2030 (E) | $7.85 | $86.5B | +8.0% | 1 | medium |
Frequently asked questions
Has AstraZeneca PLC beaten earnings estimates?
AstraZeneca PLC has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -2.0% over the last 4 quarters.
How does AZN stock react to earnings?
AZN stock has moved an average of +8.7% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is the expected EPS for AZN in 2026?
Analysts expect AstraZeneca PLC to report EPS of $5.25 for fiscal year 2026, on revenue of $64.8B, based on estimates from 1 analysts.